|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,208.00 JPY | +2.60% |
|
+2.94% | +5.49% |
| 06-30 | Trump's push for the world's lowest drug prices hits snag with mid-sized companies | RE |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| Market Cap | 3,956B 24.37B 21.34B 19.66B 18.24B 34.65B 2,324B 35.11B 235B 91.57B 1,141B 91.51B 89.5B | P/E 2027 * |
11.5x | P/E 2028 * | 12.1x |
|---|---|---|---|---|---|
| Enterprise Value | 3,879B 23.89B 20.93B 19.27B 17.89B 33.97B 2,279B 34.43B 231B 89.79B 1,119B 89.73B 87.76B | EV / Sales 2027 * |
1.72x | EV / Sales 2028 * | 1.72x |
| Free-Float |
97.66% | Yield 2027 * |
3.64% | Yield 2028 * | 3.75% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +2.60% | ||
| 1 week | +2.94% | ||
| Current month | +1.52% | ||
| 1 month | +2.17% | ||
| 3 months | -14.65% | ||
| 6 months | +3.66% | ||
| Current year | +5.49% |
| 1 week | 2,105 |  | 2,216.5 |
| 1 month | 2,041 | | 2,216.5 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,365 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.60% | +2.94% | +57.49% | +5.95% | 23.9B | |
| -0.73% | -2.01% | +55.94% | +160.18% | 1,082B | |
| -1.28% | +0.41% | +67.17% | +60.62% | 633B | |
| -2.02% | +0.17% | +35.77% | +85.61% | 461B | |
| -2.79% | +1.37% | +31.00% | +23.05% | 338B | |
| -2.46% | -1.38% | +37.99% | +36.52% | 299B | |
| -2.20% | -0.87% | +28.16% | +42.69% | 291B | |
| -1.77% | +1.97% | -27.22% | -40.66% | 222B | |
| -3.03% | +1.81% | +25.30% | +64.62% | 202B | |
| -0.51% | +2.63% | +15.99% | +70.06% | 163B | |
| Average | -1.47% | +4.04% | +32.76% | +50.86% | 371.63B | |
| Weighted average by Cap. | -1.62% | +5.40% | +41.09% | +80.20% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,250B 13.86B 12.14B 11.18B 10.38B 19.71B 1,322B 19.97B 134B 52.09B 649B 52.05B 50.91B | 2,072B 12.76B 11.18B 10.29B 9.56B 18.15B 1,217B 18.39B 123B 47.96B 598B 47.92B 46.87B |
| Net income | 345B 2.12B 1.86B 1.71B 1.59B 3.02B 202B 3.06B 20.5B 7.98B 99.39B 7.97B 7.8B | 325B 2B 1.75B 1.61B 1.5B 2.84B 191B 2.88B 19.32B 7.52B 93.66B 7.51B 7.35B |
| Net Debt | -76.78B -473M -414M -382M -354M -673M -45.12B -682M -4.57B -1.78B -22.15B -1.78B -1.74B | -391B -2.41B -2.11B -1.94B -1.8B -3.43B -230B -3.47B -23.27B -9.06B -113B -9.05B -8.85B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/07/26 | ¥2,208.00 | +2.60% | 4,506,600 |
| 03/07/26 | ¥2,152.00 | +0.58% | 5,173,500 |
| 02/07/26 | ¥2,139.50 | +0.94% | 6,188,700 |
| 01/07/26 | ¥2,119.50 | -2.55% | 5,055,800 |
| 30/06/26 | ¥2,175.00 | +0.18% | 9,968,900 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
